Kiniksa Pharmaceuticals LtdNASDAQ:KNSA
- LAST PRICE20.1000
- TODAY'S CHANGE (%)0.6200 (3.1828%)
- Bid / Lots19.5200/ 1
- Ask / Lots20.6400/ 1
- Open / Previous Close19.8000 / 19.4800
- Day Range
- 52 Week Range
- Volume254,477
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KNSA |
|---|---|---|
| 09:32 ET | 3705 | 19.8 |
| 09:34 ET | 1500 | 19.85 |
| 09:36 ET | 300 | 19.855 |
| 09:38 ET | 600 | 19.855 |
| 09:39 ET | 400 | 19.86 |
| 09:41 ET | 4300 | 19.7914 |
| 09:43 ET | 1483 | 19.8175 |
| 09:45 ET | 400 | 19.755 |
| 09:48 ET | 827 | 19.79 |
| 09:50 ET | 200 | 19.85 |
| 09:52 ET | 727 | 19.875 |
| 09:54 ET | 320 | 19.88 |
| 09:56 ET | 300 | 19.82 |
| 09:57 ET | 100 | 19.88 |
| 10:03 ET | 300 | 19.765 |
| 10:08 ET | 100 | 19.73 |
| 10:12 ET | 100 | 19.75 |
| 10:14 ET | 2362 | 19.88 |
| 10:28 ET | 100 | 19.95 |
| 10:33 ET | 6652 | 20.005 |
| 10:35 ET | 505 | 19.96 |
| 10:37 ET | 5200 | 19.93 |
| 10:39 ET | 617 | 19.9 |
| 10:42 ET | 272 | 19.94 |
| 10:44 ET | 400 | 19.91 |
| 10:48 ET | 757 | 19.92 |
| 10:50 ET | 5404 | 19.925 |
| 10:51 ET | 400 | 19.9265 |
| 10:53 ET | 3247 | 20.03 |
| 10:55 ET | 400 | 20.06 |
| 11:02 ET | 810 | 20.07 |
| 11:06 ET | 1340 | 20.06 |
| 11:08 ET | 500 | 20.08 |
| 11:11 ET | 200 | 20.06 |
| 11:13 ET | 1600 | 20.11 |
| 11:15 ET | 544 | 20.14 |
| 11:18 ET | 100 | 20.125 |
| 11:24 ET | 1100 | 20.125 |
| 11:27 ET | 100 | 20.115 |
| 11:29 ET | 100 | 20.14 |
| 11:31 ET | 109 | 20.12 |
| 11:38 ET | 317 | 20.15 |
| 11:42 ET | 200 | 20.16 |
| 11:51 ET | 300 | 20.15 |
| 11:58 ET | 1195 | 20.2 |
| 12:05 ET | 700 | 20.15 |
| 12:07 ET | 942 | 20.1403 |
| 12:09 ET | 1175 | 20.155 |
| 12:14 ET | 503 | 20.17 |
| 12:18 ET | 843 | 20.12 |
| 12:20 ET | 100 | 20.12 |
| 12:23 ET | 400 | 20.18 |
| 12:25 ET | 100 | 20.16 |
| 12:30 ET | 117 | 20.15 |
| 12:38 ET | 100 | 20.12 |
| 12:39 ET | 200 | 20.14 |
| 12:41 ET | 1000 | 20.135 |
| 12:45 ET | 100 | 20.14 |
| 12:48 ET | 1490 | 20.17 |
| 12:52 ET | 300 | 20.17 |
| 12:54 ET | 200 | 20.15 |
| 12:56 ET | 100 | 20.13 |
| 12:57 ET | 400 | 20.13 |
| 01:03 ET | 200 | 20.13 |
| 01:06 ET | 100 | 20.125 |
| 01:10 ET | 100 | 20.11 |
| 01:12 ET | 800 | 20.14 |
| 01:17 ET | 100 | 20.135 |
| 01:19 ET | 200 | 20.15 |
| 01:24 ET | 630 | 20.14 |
| 01:26 ET | 100 | 20.14 |
| 01:28 ET | 100 | 20.13 |
| 01:30 ET | 200 | 20.12 |
| 01:33 ET | 106 | 20.13 |
| 01:37 ET | 225 | 20.12 |
| 01:42 ET | 300 | 20.13 |
| 01:44 ET | 200 | 20.12 |
| 01:46 ET | 4000 | 20.06 |
| 01:53 ET | 3242 | 20.085 |
| 01:55 ET | 100 | 20.08 |
| 02:00 ET | 100 | 20.09 |
| 02:02 ET | 600 | 20.09 |
| 02:04 ET | 100 | 20.1068 |
| 02:11 ET | 200 | 20.15 |
| 02:18 ET | 1000 | 20.14 |
| 02:22 ET | 543 | 20.1216 |
| 02:27 ET | 1639 | 20.17 |
| 02:33 ET | 1000 | 20.2 |
| 02:49 ET | 900 | 20.24 |
| 02:54 ET | 928 | 20.27 |
| 02:58 ET | 200 | 20.27 |
| 03:02 ET | 100 | 20.24 |
| 03:03 ET | 705 | 20.23 |
| 03:05 ET | 100 | 20.23 |
| 03:07 ET | 100 | 20.24 |
| 03:09 ET | 400 | 20.225 |
| 03:14 ET | 100 | 20.24 |
| 03:16 ET | 300 | 20.21 |
| 03:18 ET | 600 | 20.19 |
| 03:21 ET | 204 | 20.14 |
| 03:23 ET | 414 | 20.155 |
| 03:30 ET | 400 | 20.14 |
| 03:34 ET | 1300 | 20.105 |
| 03:36 ET | 1400 | 20.065 |
| 03:38 ET | 400 | 20.04 |
| 03:39 ET | 940 | 20.06 |
| 03:41 ET | 309 | 20.05 |
| 03:43 ET | 100 | 20.04 |
| 03:45 ET | 400 | 20.06 |
| 03:48 ET | 400 | 20.07 |
| 03:50 ET | 407 | 20.074 |
| 03:52 ET | 1833 | 20.1 |
| 03:54 ET | 811 | 20.12 |
| 03:56 ET | 3323 | 20.105 |
| 03:57 ET | 3279 | 20.1 |
| 03:59 ET | 66434 | 20.1 |
May 7, 2024
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference, from 4:01PM ET on Tuesday May 07, 2024 by Dow Jones
4:01PM ET on Tuesday May 07, 2024 by Dow Jones
May 3, 2024
DJ Kiniksa Pharmaceuticals Initiated at Overweight by Wells Fargo, from 11:59AM ET on Friday May 03, 2024 by Dow Jones
11:59AM ET on Friday May 03, 2024 by Dow Jones
May 1, 2024
DJ Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan, from 10:58AM ET on Wednesday May 01, 2024 by Dow Jones
10:58AM ET on Wednesday May 01, 2024 by Dow Jones
Apr 24, 2024
DJ Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group, from 1:50PM ET on Wednesday Apr 24, 2024 by Dow Jones
1:50PM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 23, 2024
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution, from 7:30AM ET on Tuesday Apr 23, 2024 by Dow Jones
7:30AM ET on Tuesday Apr 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.4B | 235.9x | --- |
Dynavax Technologies Corp | 1.4B | 221.0x | --- |
MiMedx Group Inc | 1.2B | 21.4x | --- |
MannKind Corp | 1.2B | 189.9x | --- |
Ginkgo Bioworks Holdings Inc | 1.9B | -1.9x | --- |
CareDx Inc | 793.8M | -4.3x | --- |
Company Information
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Contact Information
- Headquarters
- Clarendon House, 2 Church StreetHAMILTON, Bermuda HM11
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Sanjiv Patel
- Chief Financial Officer, Senior Vice President
- Mark Ragosa
- Chief Operating Officer, Senior Vice President
- Eben Tessari
- Senior Vice President and Chief Commercial Officer
- Ross Moat
- Senior Vice President and Chief Medical Officer
- John Paolini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
|---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.33 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 235.9x |
Price/Sales (TTM) | 4.6 |
Price/Cash Flow (TTM) | 127.2x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
